Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Zaragoza – page 36

546 clinical trials in Zaragoza, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Zaragoza at a glance
546
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

546 trials in Zaragoza

Open in trial search

Hepatocellular carcinoma

Not recruiting

Study on Advanced Liver Cancer: Evaluating Livmoniplimab and Budigalimab in Patients Without Prior Systemic Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol Myers Squibb International Corporation

Dementia Alzheimer's type

Not recruiting

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Richter's syndrome

Not recruiting

Study of Mosunetuzumab and Drug Combination for Untreated Patients with Richter's Syndrome

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Grupo Espanol De Leucemia Linfocitica Cronica

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Gaucher's disease type III+1

Not recruiting

Study of Eliglustat alone or with Imiglucerase in children and adolescents aged 2-17 years with Gaucher disease type 1 and type 3

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Eliglustat Tartrate
  • Sponsor:Genzyme Corp.

Chronic obstructive pulmonary disease

Not recruiting

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gaucher's disease type I

Not recruiting

Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
  • Sponsor:Spur Therapeutics Limited

Metastatic malignant melanoma

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Io102 Hydrochloride
  • Sponsor:Io Biotech ApS

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Zaragoza

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on advanced cancer treatments and blood disorders, including studies of new therapies for lung cancer, pancreatic adenocarcinoma, and various hematologic malignancies.

  • Non-small cell lung cancer treatments
  • Chronic lymphocytic leukemia therapies
  • Soft tissue sarcoma management

Multiple trials evaluating combination therapies and novel treatment approaches for both solid tumors and blood cancers.

02 Autoimmune & Inflammatory Conditions

Research into treatments for various inflammatory and autoimmune disorders, with emphasis on chronic conditions affecting quality of life.

  • Plaque psoriasis treatments
  • Crohn's disease management
  • Thyroid eye disease therapies

Studies focusing on innovative biological therapies and targeted treatments for inflammatory conditions.

03 Cardiovascular & Metabolic Disorders

Studies addressing critical cardiovascular health challenges and metabolic conditions, including innovative approaches to stroke treatment and lipid management.

  • Acute cerebral ischemic stroke
  • Hypertriglyceridemia treatments
  • Cardiovascular disease prevention

Focus on developing new therapeutic options for both acute and chronic cardiovascular conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.